|Daily Range||$35.42 - $35.81|
|52-Week Range||$33.23 - $38.71|
|Dividend (Yield)||$0.00 (2.6%)|
|Average Daily Volume||2,238,147|
|Current FY EPS||$2.00|
News & Commentary
The good news: this beverage reduced the risk of an aggressive form of skin cancer by 20% in a very large study. The better news: 83% of you are already consuming this beverage on a daily basis!
Global cancer drug sales totaled $91 billion in 2013 and are expected to breach $100 billion in sales sooner than you think. Yet, three big pharmaceutical companies currently control about half of all cancer drug sales.
Have you ever wondered why the effectiveness of the flu vaccine is so erratic from one year to the next? Here's the answer.
There are plenty of companies developing precision medicine drugs already, and investors would be wise to watch key players.
Three Motley Fool analysts help investors spot biotech stock warning signals.
It could happen, but here's why long-term investors should ignore this noise anyway.
Pfizer's pipeline currently features 86 clinical studies and/or registrations. That's an incredible figure that demonstrates Pfizer's commitment to R&D. But, it's also not the most robust pipeline in the pharmaceutical sector. Can you guess which big pharma company has an even larger pipeline than Pfizer?
Shares of cancer diagnostic maker Foundation Medicine more than doubled Monday morning. Here's why.
ImmunoGen was the worst biotech stock in December after it and its partner Roche released disappointed study data. Find out whether the mauling was merited or if ImmunoGen shares could be a bargain here.
With its shares up 500% over the past two years, is Inovio poised for more upside or a 50% haircut?